DIGITALDX
  • People
    • TEAM >
      • Michele Colucci
      • Eric Weiss
      • Anula Jayasuriya
      • Vanessa Small
      • David Kirk
      • Melody Po
      • Sharad Mishra
      • Maureen Downey
      • Valerie Kozak
      • Vivian Lu
    • EIR >
      • Jerry Lanchbury
      • Debbie Lin
      • Michael Doherty
      • Laura Yecies
      • Jean Machart
      • Laura Mezey
      • Ramin Khaksar
      • Alissa Hsu Lynch
      • Anita Samarth
      • L. Jasmine Kim
      • Swami Raote
      • Mrunalini Parvataneni
      • Doug Ross
      • Scott Ashworth
      • Richard Frank
    • Advisors >
      • Deborah DiSanzo
      • Russ Altman
      • Rebecca Maciera-Kaufman
      • Saul A. Fox
      • Girish Narayan
      • Maureen A. Spivack
      • Ferid Murad
      • Ronald Wyatt
    • Fellows >
      • Apply for Fellowship
  • Focus
    • About Us
    • Market Opportunity
    • Market Segmentation
  • Portfolio
    • Portfolio Companies
    • News
  • Impact
    • ESG + DEI
    • Gender Parity
  • Press
    • Press Releases
    • Events/Video
Picture
* Market Opportunity: 1 in 3 seniors die of Alzheimer's or another dementia, 5.7M/year in the US alone, no accurate diagnosis exists
​* Technology: Diagnosis of dementia 8-10 years before it is apparent
* Management Team: GE, Eli Lilly, Zimmer, JMP Securities

Market Opportunity: Alzheimer's is the 6th leading cause of death in the U.S. 1 in 3* seniors die of Alzheimer's or another dementia. It kills more people than breast and prostate cancer combined. An estimated 5.7M Americans of all ages are living with Alzheimer’s dementia in 2018 (5.5M > 65 years old and approximately 200K < 65 years).  In 2018, Alzheimer’s and other dementia will cost the nation $277B.* Early and accurate diagnosis could save up to $7.9T* in medical and care costs.

Technology: This Company has a diagnostic that can see the very beginning of Alzheimer’s disease starting 8-10 years before any dementia is apparent. The test is very easy and painless to do, and costs only $100-$200. The current standard is a PET with a radioactive marker that costs $3,000+ and involves toxic chemicals, and it cannot see the disease progression until later in its development. Most doctors don’t have easy access to a PET scanner. This novel early diagnosis allows a doctor to change medications, diet and exercise levels to delay the onset of the disease.

Currently, the Company has the world’s first/best demonstration of cerebral amyloid detection (vs blood tests). The Company has received strong positive feedback from academia and pharma at the Human Imaging Conference. The AAIC abstract recently submitted represents the best data on amyloid detection beside PET scan and CSF. Mayo Clinic and MGH have committed to deliver a large number of subjects at no cost to the Company.

Big pharma companies have over 25 new drugs in Phase 3 trials that will be able to treat the disease in the next few years. So this test for early detection will be even more valuable.

Management Team: The company is led by proven operators from GE, Eli Lilly, Zimmer and JMP Securities.

David Kirk is a Board Observer; Michele Colucci is a Board Member
​

*Source: Alzheimer’s Association. 2018 Alzheimer’s Disease Facts and Figures
(1) Current investment from DigitalDX
Disclaimer
Terms & Conditions
Privacy Policy
Investment Inquiries
Contact
Picture
Picture
Picture
 Copyright © 2022 All Rights Reserved
  • People
    • TEAM >
      • Michele Colucci
      • Eric Weiss
      • Anula Jayasuriya
      • Vanessa Small
      • David Kirk
      • Melody Po
      • Sharad Mishra
      • Maureen Downey
      • Valerie Kozak
      • Vivian Lu
    • EIR >
      • Jerry Lanchbury
      • Debbie Lin
      • Michael Doherty
      • Laura Yecies
      • Jean Machart
      • Laura Mezey
      • Ramin Khaksar
      • Alissa Hsu Lynch
      • Anita Samarth
      • L. Jasmine Kim
      • Swami Raote
      • Mrunalini Parvataneni
      • Doug Ross
      • Scott Ashworth
      • Richard Frank
    • Advisors >
      • Deborah DiSanzo
      • Russ Altman
      • Rebecca Maciera-Kaufman
      • Saul A. Fox
      • Girish Narayan
      • Maureen A. Spivack
      • Ferid Murad
      • Ronald Wyatt
    • Fellows >
      • Apply for Fellowship
  • Focus
    • About Us
    • Market Opportunity
    • Market Segmentation
  • Portfolio
    • Portfolio Companies
    • News
  • Impact
    • ESG + DEI
    • Gender Parity
  • Press
    • Press Releases
    • Events/Video